Your browser doesn't support javascript.
loading
Treatment of BRAF V600E mutant gastrointestinal stromal tumor with dabrafenib: a case report.
Gowda, Sonia; Sandow, Lyndsey; Heinrich, Michael C.
Afiliación
  • Gowda S; Oregon Health and Science University Knight Cancer Institute, Portland, OR, USA.
  • Sandow L; Oregon Health and Science University Knight Cancer Institute, Portland, OR, USA.
  • Heinrich MC; Oregon Health and Science University Knight Cancer Institute, Portland, OR, USA.
J Gastrointest Oncol ; 15(2): 788-793, 2024 Apr 30.
Article en En | MEDLINE | ID: mdl-38756640
ABSTRACT

Background:

Gastrointestinal stromal tumor (GIST) is a rare mesenchymal tumor arising in the gut, most commonly stomach or small bowel. The most common driver mutations are KIT and PDGFRA which can be treated with imatinib or avapritinib (for PDGFRA D842V-mutant GIST), respectively. BRAF V600E mutant GISTs are rare and these do not respond to imatinib. Multiple clinical trials have shown antitumor effects with dabrafenib in BRAF-mutant melanoma and a few case reports have demonstrated treatment of BRAF V600E mutant GIST with a BRAF kinase inhibitor. Case Description We present a case of a 67-year-old woman diagnosed with high-risk GIST following initial resection. She was initially treated with adjuvant imatinib which was discontinued after 7 months because molecular analysis of her tumor showed the absence of KIT and PDGFRA mutations and a BRAF V600E mutation. When her disease progressed, she was started on sunitinib and subsequently regorafenib. Both agents were discontinued due to severe palmar-plantar erythrodysesthesia and clinical progression. She was subsequently started on dabrafenib based on the presence of a BRAF V600E mutation; this therapy led to a partial response. Her disease remained stable on this medication for 19 months before progression and addition of trametinib to her treatment. Her disease continued to progress and she was switched to everolimus with mixed response before re-challenging with dabrafenib and trametinib. Her imaging showed a mixed response to the re-challenge before progressing after 5 months and transitioning to hospice.

Conclusions:

We describe an uncommon molecular subtype of GIST with a BRAF V600E mutation. As expected, her disease was resistant to standard GIST therapy, however there was notable tumor regression following treatment with dabrafenib. This case shows the importance of molecular testing in GIST and adds to the current body of literature on the treatment of BRAF-mutant GIST.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Gastrointest Oncol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: China

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Gastrointest Oncol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: China